Search | Clinical Trials Finder

Conditions: McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
Interventions: Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test; Procedure · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Impaired Glucose Tolerance
Interventions: All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.; Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus, Obese, Overweight
Interventions: Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium, Placebo; Radiation · Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition, Control- Stimulation, Experimental I- Stimulation, Experimental II- Stimulation, Sensory Evaluation; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Gestational Diabetes
Interventions: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Acromegaly
Interventions: Oral glucose tolerance test; Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, Gestational
Interventions: Dexcom G6; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions: oral glucose tolerance test, MRI of liver; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes
Interventions: Hypoxico Altitude Training Systems; Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Baton Rouge, Louisiana

Conditions: Obesity
Interventions: Oral glucose tolerance test, Cognitive testing, Magnetic resonance imaging; Procedure · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Aging
Interventions: Vitamin D3 (cholecalciferol), fish oil; Dietary Supplement · Drug
Lead sponsor: Augusta University; Other
Eligibility: 50 Years and older
Enrollment: 1,054 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: PreDiabetes
Interventions: Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg; Drug
Lead sponsor: Philip Kern; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Interventions: Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test; Procedure
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 19 Years to 59 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Diabetes Mellitus, Type 2
Interventions: Glipizide, Metformin, Oral Glucose Tolerance Test; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Pre-diabetes
Interventions: Oral glucose tolerance test; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole; Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Overweight and Obesity, PreDiabetes, Insulin Resistance
Interventions: CGM; Device
Lead sponsor: Mary Ellen Vajravelu, MD; Other
Eligibility: 8 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non Alcoholic Fatty Liver Disease
Interventions: ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy; Other
Lead sponsor: Yale University; Other
Eligibility: 7 Years to 18 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire; Diagnostic Test · Other · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 23
States / cities: Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage; Drug · Device · Diagnostic Test + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 22,220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Cancer
Interventions: Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

Role of Sweetness in Glucose Regulation

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance

Post-Prandial Liver Glucose Metabolism in PCOS

Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes

Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity

Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL

Mechanisms for Activation of Beige Adipose Tissue in Humans

Stable Isotopes- Adults With Obesity

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

Common Genetic Variation and Type 2 Diabetes

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation

Genetics of Fatty Liver Disease in Children

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Blood Markers of Early Pancreas Cancer

Effect of Alpelisib in Healthy Volunteers

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant